Teleflex (TFX) Director George Babich, Jr. Sells 2,500 Shares of Stock

Teleflex (NYSE:TFX) Director George Babich, Jr. sold 2,500 shares of the firm’s stock in a transaction on Monday, April 23rd. The stock was sold at an average price of $270.66, for a total value of $676,650.00. Following the transaction, the director now owns 9,358 shares in the company, valued at $2,532,836.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of TFX opened at $263.37 on Wednesday. The firm has a market cap of $12,209.70, a PE ratio of 31.35, a price-to-earnings-growth ratio of 2.00 and a beta of 1.17. The company has a current ratio of 2.33, a quick ratio of 1.51 and a debt-to-equity ratio of 0.89. Teleflex has a one year low of $191.40 and a one year high of $288.78.

How to Become a New Pot Stock Millionaire

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, February 22nd. The medical technology company reported $2.44 EPS for the quarter, beating analysts’ consensus estimates of $2.40 by $0.04. The company had revenue of $595.10 million for the quarter, compared to analyst estimates of $601.17 million. Teleflex had a return on equity of 16.46% and a net margin of 7.11%. The company’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same period last year, the company earned $2.13 earnings per share. sell-side analysts anticipate that Teleflex will post 9.66 EPS for the current year.

A number of equities research analysts have issued reports on the company. Leerink Swann reiterated a “buy” rating and issued a $321.00 target price (up from $307.00) on shares of Teleflex in a research note on Tuesday, January 30th. Stephens reiterated a “buy” rating and issued a $300.00 target price on shares of Teleflex in a research note on Thursday, January 18th. TheStreet cut Teleflex from an “a-” rating to a “c+” rating in a research note on Monday, March 12th. ValuEngine cut Teleflex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Finally, Goldman Sachs assumed coverage on Teleflex in a research note on Wednesday, April 4th. They issued a “neutral” rating and a $257.00 target price on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $279.10.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its holdings in Teleflex by 3.4% during the fourth quarter. BlackRock Inc. now owns 4,709,341 shares of the medical technology company’s stock worth $1,171,779,000 after acquiring an additional 156,527 shares during the period. American Century Companies Inc. grew its holdings in Teleflex by 24.1% during the fourth quarter. American Century Companies Inc. now owns 1,474,609 shares of the medical technology company’s stock worth $366,912,000 after acquiring an additional 286,700 shares during the period. Geode Capital Management LLC grew its holdings in Teleflex by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 398,866 shares of the medical technology company’s stock worth $99,192,000 after acquiring an additional 9,515 shares during the period. William Blair Investment Management LLC acquired a new position in Teleflex during the fourth quarter worth about $53,163,000. Finally, Renaissance Technologies LLC grew its holdings in Teleflex by 511.6% during the fourth quarter. Renaissance Technologies LLC now owns 195,700 shares of the medical technology company’s stock worth $48,694,000 after acquiring an additional 163,700 shares during the period. 90.49% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://weekherald.com/2018/04/25/teleflex-tfx-director-george-babich-jr-sells-2500-shares-of-stock.html.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply